bioAffinity Technologies, Inc.
BIAF- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001712762
No open-market purchases or sales by bioAffinity Technologies, Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $782.5K in total; no superinvestor holds it.
Other share classesBIAFW
Q2 2024 vs. Q1 2024
How the institutions holding bioAffinity Technologies, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 14 | 17 | +3 |
| Shares | 239.7K | 399.7K | +160.0K (+66.8%) |
| Value | $484.4K | $863.3K | +$378.9K (+78.2%) |
New holders (5)
Institutions that held bioAffinity Technologies, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ground Swell Capital, LLC | 22,864 | $49.4K | 0.05% |
| UBS Group AG | 9,591 | $20.7K | 0.00% |
| Morgan Stanley | 1,000 | $2.16K | 0.00% |
| Cypress Capital, LLC | 200 | $432 | 0.00% |
| Bank of America Corp | 65 | $140 | 0.00% |
Sold out (2)
Institutions that held bioAffinity Technologies, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Clear Street LLC | 100 | $202 |
| Wells Fargo & Company | 45 | $91 |